Resultados: 8

    The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin

    Tuberculosis (TB) remains a large-scale public health problem. Key global priorities for TB care and control include improving case-detection and detecting cases earlier, including cases of smear-negative disease. This document updates existing WHO policy on the use of molecular LPAs for detecting MTBC a...

    WHO treatment guidelines for drug-resistant tuberculosis, 2016 update

    In November 2015, the World Health Organization (WHO) convened a meeting of a Guideline Development Group (GDG) for the update of policy recommendations on the treatment of drug-resistant TB. The GDG was composed of a multidisciplinary group of tuberculosis (TB) and drug-resistant TB experts external to ...

    The use of delamanid in the treatment of multidrug-resistant tuberculosis: interim policy guidance

    The aim of this guidance is to provide the interim principles that should guide the use of delamanid in conjunction with WHO-recommended MDR-TB treatment. It also specifies the essential treatment and management conditions for use of this drug, in particular the patient's eligibility criteria and safety ...

    The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: Interim policy guidance

    WHO estimates that up to half a million new cases of multidrug-resistant tuberculosis (MDR-TB) occur worldwide, each year. Current treatment regimens for MDR-TB present many challenges: treatment lasts 20 months or more, requiring daily administration of drugs that are more toxic, less effective, and far...

    Guidelines for the programmatic management of drug-resistant tuberculosis – 2011 update

    This 2011 update of Guidelines for the programmatic management of drug-resistant tuberculosis is intended as a tool for use by public health professionals working in response to the Sixty-second World Health Assembly’s resolution on prevention and control of multidrug-resistant tuberculosis and extensi...

    Noncommercial culture and drug-susceptibility testing methods for screening patients at risk for multidrug-resistant tuberculosis: policy statement

    Commercial liquid culture systems and molecular line-probe assays have been endorsed by the World Health Organization (WHO) as gold standards for rapid detection of multidrug-resistant (MDR) tuberculosis (TB); however, because of technical complexity, cost and the requirement for sophisticated laboratory...

    Management of MDR-TB: a field guide: a companion document to guidelines for programmatic management of drug-resistant tuberculosis: integrated management of adolescent and adult illness (‎IMAI)‎

    Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) increasingly occur in resource-constrained settings. In the context of a national response to MDR- and XDR-TB, health workers in TB clinics (in district hospitals and some accredited health centres) will need t...